Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 crossover study of apadamtase alfa for prophylactic and on-demand treatment of severe congenital thrombotic thrombocytopenic purpura
2017-000858-18Phase 3Unknown
- Sponsor
- Baxalta
- Start
- Jul 2017
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Apadamtase alfa in Upshaw-Schulman syndrome (USS) (3 arms), sponsored by Baxalta. Primary endpoint: Incidence of acute TTP episodes during prophylaxis. Status: unknown.
02
Drugs
Apadamtase alfa
03
Conditions
Upshaw-Schulman syndrome (USS)
Beyond the preview
Go deeper on 2017-000858-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000858-18.